Growth-factor gene therapy for neurodegenerative disorders

Lancet Neurology

Volumn 1, Issue 1, 2002, Pages 51-57

  Tuszynski, Mark H ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT NERVE GROWTH FACTOR; GROWTH PROMOTOR;

AGING; ALZHEIMER DISEASE; BRAIN FORNIX; CANCER; CELL LOSS; CELL TRANSPLANTATION; CHOLINERGIC NERVE CELL; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG RESEARCH; FIBROBLAST; FOREBRAIN; GENE DELIVERY SYSTEM; GENE TARGETING; GENE TECHNOLOGY; GENE THERAPY; HOST CELL; HUMAN; HUNTINGTON CHOREA; IATROGENIC DISEASE; INFUSION; INTERMETHOD COMPARISON; MEDICAL RESEARCH; NERVE CELL DEGENERATION; NERVE DEGENERATION; NERVE FUNCTION; NEUROLOGIC DISEASE; NONHUMAN; PAIN; PARKINSON DISEASE; PRIMATE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; TARGET CELL; TUMOR; WEIGHT REDUCTION; ANIMAL; ARTICLE; BRAIN; DRUG EFFECT; GENETICS; METHODOLOGY; PATHOLOGY; STATISTICS;

ANIMALS; BRAIN; CLINICAL TRIALS; GENE THERAPY; GROWTH SUBSTANCES; HUMANS; NEURODEGENERATIVE DISEASES;

EID: 0037654372     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(02)00006-6     Document Type: Review

References (72)

1. Levi-Montalcini R., Hamburger V. Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. J Exp Zool. 116:1951;321-362.
2. Levi-Montalcini R. The nerve growth factor 35 years later. Science. 237:1987;1154-1162.
3. Angeletti R.H., Hermodson M.A., Bradshaw R.A. Amino acid sequences of mouse 2.5S nerve growth factor. II, isolation and characterization of the thermolytic and peptic peptides and the complete covalent structure. Biochemistry. 12:1973;100-115.
4. Ullrich A., Gray A., Berman C., Dull T.J. Human beta-nerve growth factor gene sequence highly homologous to that of mouse. Nature. 303:1983;821-825.
5. Schwab M.E., Otten U., Agid Y., Thoenen H. Nerve growth factor (NGF) in the rat CNS: absence of specific retrograde axonal transport and tyrosine hydroxylase induction in locus coeruleus and substantia nigra. Brain Res. 168:1979;473-483.
6. Scott S.M., Tarris R., Eveleth D., Mansfield H., Weichsel M.E., Fisher D.A. Bioassay detection of mouse nerve growth factor (mNGF) in the brain of adult mice. J Neurosci Res. 6:1981;653-658.
7. Crutcher K.A., Collins F. In vitro evidence for two distinct hippocampal growth factors: basis of neuronal plasticity? Science. 217:1982;67-68.
8. Ayer LeLievre C.S., Ebendal T., Olsen L., Seiger A. Localization of NGF-like immunoreactivity in rat neuronal tissue. Med Biol. 61:1983;296-304.
9. Gnahn H., Hefti F., Heumann R., Schwab M.E., Thoenen H. NGF-mediated increase of choline acetyltransferase (ChAT) in the neonatal rat forebrain: evidence for a physiological role of NGF in the brain? Brain Res. 285:1983;45-52.
10. Seiler M., Schwab M.E. Specific retrograde transport of nerve growth factor (NGF) from cortex to nucleus basalis in the rat. Brain Res. 300:1984;33-39.
11. Hefti F. Nerve growth factor (NGF) promotes survival of septal cholinergic neurons after fimbrial transection. J Neurosci. 6:1986;2155-2162.
12. Williams L.R., Varon S., Peterson G.M., et al. Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria-fornix transection. Proc Natl Acad Sci USA. 83:1986;9231-9235.
13. Kromer L.F. Nerve growth factor treatment after brain injury prevents neuronal death. Science. 235:1987;214-216.
14. Fischer W., Wictorin K., Bjorklund A., Williams L.R., Varon S., Gage F.H. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature. 329:1987;65-68.
15. Hefti F., Weiner W.J. Nerve growth factor and Alzheimer's disease. Ann Neurol. 20:1986;275-281.
16. Phelps C.H., Gage F.H., Growdon H., et al. Potential use of nerve growth factor to treat Alzheimer's disease. Neurobiol Aging. 10:1989;205-207.
17. Whitehouse P.J., Price D.L., Struble R.G., Clar A.W., Coyle J.T., Delong M.R. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. 215:1982;1237-1239.
18. Bartus R., Dean R.L., Beer C., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science. 217:1982;408-417.
19. Emmett C.J., Stewart G.R., Johnson R.M., Aswani S.P., Chan R.L., Jakeman L.B. Distribution of radioiodinated recombinant human nerve growth factor in primate brain following intracerebroventricular infusion. Exp Neurol. 140:1996;151-160.
20. Tuszynski M.H., HS U., Amaral D.G., Gage F.H. Nerve growth factor infusion in primate brain reduces lesion-induced cholinergic neuronal degeneration. J Neurosci. 10:1990;3604-3614.
21. Koliatsos V.E., Nauta H.J., Clatterbuck R.E., Holtzman D.M., Mobley W.C., Price D.L. Mouse nerve growth factor prevents degeneration of axotomized basal forebrain cholinergic neurons in the monkey. J Neurosci. 10:1990;3801-3813.
22. Tuszynski M.H., H-S U., Gage F.H. Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain. Ann Neurol. 30:1991;625-636.
23. Isaacson L.G., Saffran B.N., Crutcher K.A. Intracerebral NGF infusion induces hyperinnervation of cerebral blood vessels. Neurobiol Aging. 11:1990;51-55.
24. Williams L.R. Hypophagia is induced by intracerebroventricular administration of nerve growth factor. Exp Neurol. 113:1991;31-37.
25. Winkler J., Ramirez G.A., Kuhn H.G., et al. Reversible induction of Schwann cell hyperplasia and sprouting of sensory and sympathetic neurites in vivo after continuous intracerebroventricular administration of nerve growth factor. Ann Neurol. 40:1996;128-139.
26. Emmett C.J., Stewart G.R., Johnson R.M., Aswani S.P., Chan R.L., Jakeman L.B. Distribution of radioiodinated recombinant human nerve growth factor in primate brain following intracerebroventricular infusion. Exp Neurol. 140:1996;151-160.
27. Eriksdotter Jonhagen M., Nordberg A., Amberla K., et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 9:1998;246-257.
28. Blesch A., Grill R.J., Tuszynski M.H. Neurotrophin gene therapy in models of CNS trauma and neurodegeneration. Prog Brain Res. 117:1998;473-484.
29. Brustle O., McKay R.D. Neuronal progenitors as tools for cell replacement in the nervous system. Curr Opin Neurobiol. 6:1996;688-695.
30. Rosenberg M.B., Friedmann T., Robertson R.C., et al. Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression. Science. 242:1988;1575-1578.
31. Chen K.S., Gage F.H. Somatic gene transfer of NGF to the aged brain: behavioral and morphological amelioration. J Neurosci. 15:1995;2819-2825.
32. Tuszynski M.H., Roberts J., Senut M.C., H-S U., Gage F.H. Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration. Gene Ther. 3:1996;305-314.
33. Emerich D.W., Winn S., Harper J., Hammang J.P., Baetge E.E., Kordower J.H. Implants of polymer-encapsulated human NGF-secreting cells in the nonhuman primate: rescue and sprouting of degenerating cholinergic basal forebrain neurons. J Comp Neurol. 349:1994;148-164.
34. Kordower J.H., Winn S.R., Liu Y.-T., et al. The aged monkey basal forebrain: rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor. Proc Natl Acad Sci USA. 91:1994;10898-10902.
35. Smith D.E., Roberts J., Gage F.H., Tuszynski M.H. Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy. Proc Natl Acad Sci USA. 96:1999;10893-10898.
36. Mesulam M.M., Mufson E.J., Levey A.I., Wainer B.H. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol. 214:1983;170-197.
37. Mufson E.J., Conner J.M., Kordower J.H. Nerve growth factor in Alzheimer's disease: defective retrograde transport to nucleus basalis. Neuroreport. 6:1995;1063-1066.
38. Scott S.A., Mufson E.J., Weingartner J.A., Skau K.A., Crutcher K.A. Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis. J Neurosci. 15:1995;6213-6221.
39. Tuszynski M.H. Neurotrophic factors. Tuszynski M.H., Kordower J.H. CNS regeneration: basic science and clinical advances. 1999;109-158 Academic Press, San Diego.
40. Kordower J.H., Emborg M.E., Bloch J., et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science. 290:2000;767-773.
41. Emerich D.F., Winn S.R., Hantraye P.M., et al. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature. 386:1997;395-399.
42. Yan Q., Matheson C., Lopez O.T. In vivo neurotrophic effects of GDNF on neonatal and adult facial motor neurons. Nature. 373:1995;341-344.
43. Grill R., Murai K., Blesch A., Gage F.H., Tuszynski M.H. Cellular delivery of neurotrophin-3 promotes corticospinal axonal growth and partial functional recovery after spinal cord injury. J Neurosci. 17:1997;5560-5572.
44. Liu Y., Kim D., Himes B.T., et al. Transplants of fibroblasts genetically modified to express BDNF promote regeneration of adult rat rubrospinal axons and recovery of forelimb function. J Neurosci. 19:1999;4370-4387.
45. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology. 46:1996;1244-1249.
46. A controlled trial of recombinant methionyl human BDNF in ALS. Neurology. 52:1999;1427-1433.
47. Lai E.C., Felice K.J., Festoff B.W., et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS.A placebo-controlled study. Neurology. 49:1997;1621-1630.
48. Miller R.G. Carrell-Krusen Symposium invited lecture. Clinical trials in motor neuron diseases. J Child Neurol. 14:1999;173-179.
49. Olson L., Nordberg A., von Holst H., et al. Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer's patient. J Neural Transm. 4:1992;79-95.
50. Apfel S.C., Kessler J.A., Adornato B.T., Litchy W.J., Sanders C., Rask C.A. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. Neurology. 51:1998;695-702.
51. Bensa S., Hadden R.D., Hahn A., Hughes R.A., Willison H.J. Randomized controlled trial of brain-derived neurotrophic factor in Guillain-Barre syndrome: a pilot study. Eur J Neurol. 7:2000;423-426.
52. Chaudhry V., Giuliani M., Petty B.G., et al. Tolerability of recombinant-methionyl human neurotrophin-3 (r-metHuNT3) in healthy subjects. Muscle Nerve. 23:2000;189-192.
53. Wellmer A., Misra V.P., Sharief M.K., Kopelman P.G., Anand P. A double-blind placebo-controlled clinical trial of recombinant human brain-derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy. J Peripher Nerv Syst. 6:2001;204-210.
54. Ay H., Ay I., Koroshetz W.J., Finklestein S.P. Potential usefulness of basic fibroblast growth factor as a treatment for stroke. Cerebrovasc Dis. 9:1999;131-135.
55. Short M.P., Choi B.C., Lee J.K., Malick A., Breakefield X.O., Martuza R.L. Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J Neurosci Res. 27:1990;427-439.
56. Culver K.W., Ram Z., Wallbridge S., Ishii H., Oldfield E.H., Blaese R.M. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 256:1992;1550-1552.
57. Nanda D., Driesse M.J., Sillevis Smitt P.A. Clinical trials of adenoviral-mediated suicide gene therapy of malignant gliomas. Prog Brain Res. 132:2001;699-710.
58. Alavi J.B., Eck S.L. Gene therapy for high grade gliomas. Expert Opin Biol Ther. 1:2001;239-252.
59. Leone P., Janson C.G., Bilaniuk L., et al. Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease. Ann Neurol. 48:2000;27-38.
60. Li T., Davidson B.L. Phenotype correction in retinal pigment epithelium in murine mucopolysaccharidosis VII by adenovirus-mediated gene transfer. Proc Natl Acad Sci USA. 92:1995;7700-7704.
61. Learish R., Ohashi T., Robbins P.A., et al. Retroviral gene transfer and sustained expression of human arylsulfatase A. Gene Ther. 3:1996;343-349.
62. Lacorazza H.D., Flax J.D., Snyder E.Y., Jendoubi M. Expression of human beta-hexosaminidase alpha-subunit gene (the gene defect of Tay-Sachs disease) in mouse brains upon engraftment of transduced progenitor cells. Nat Med. 2:1996;424-429.
63. Hahn C.N., del Pilar Martin M., Zhou X.Y., Mann L.W., d'Azzo A. Correction of murine galactosialidosis by bone marrow-derived macrophages overexpressing human protective protein/cathepsin A under control of the colony-stimulating factor-1 receptor promoter. Proc Natl Acad Sci USA. 95:1998;14880-14885.
64. Stein C.S., Ghodsi A., Derksen T., Davidson B.L. Systemic and central nervous system correction of lysosomal storage in mucopolysaccharidosis type VII mice. J Virol. 73:1999;3424-3429.
65. Daly T.M., Vogler C., Levy B., Haskins M.E., Sands M.S. Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. Proc Natl Acad Sci USA. 96:1999;2296-2300.
66. Takenaka T., Murray G.J., Qin G., et al. Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. Proc Natl Acad Sci USA. 97:2000;7515-7520.
67. Consiglio A., Quattrini A., Martino S., et al. In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice. Nat Med. 7:2001;310-316.
68. Allamand V., Donahue K.M., Straub V., Davisson R.L., Davidson B.L., Campbell K.P. Early adenovirus-mediated gene transfer effectively prevents muscular dystrophy in alpha-sarcoglycan-deficient mice. Gene Ther. 7:2000;1385-1391.
69. O'Connor W.M., Davidson B.L., Kaplitt M.G., et al. Adenovirus vector-mediated gene transfer into human epileptogenic brain slices: prospects for gene therapy in epilepsy. Exp Neurol. 148:1997;167-178.
70. Betz A.L., Yang G.Y., Davidson B.L. Attenuation of stroke size in rats using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist in brain. J Cereb Blood Flow Metab. 15:1995;547-551.
71. Gossen M., Bonin A.L., Freundlieb S., Bujard H. Inducible gene expression systems for higher eukaryotic cells. Curr Opin Biotechnol. 5:1994;516-520.
72. Blesch A., Conner J.M., Tuszynski M.H. Modulation of neuronal survival and axonal growth in vivo by tetracycline-regulated neurotrophin expression. Gene Ther. 8:2001;954-960.